Pacira (PRCX) Bullish Stance Reiterated at Piper Jaffray on Surgeon Feedback
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Goldman Sachs Starts Pacira Pharmaceuticals (PCRX) at Buy
June 2, 2014 8:07 AM EDTGoldman Sachs initiates coverage on Pacira Pharmaceuticals (NASDAQ: PCRX) with a Buy rating and a price target of $93.00.
Analyst Gary Nachman said, "We believe key product Exparel, a long-acting bupivacaine injection for postsurgical pain, is poised to continue on a very strong growth... More
